Physician profile
Raphael J Higginbotham
NPI 1477507531
$6,495.36
in general payments reported to CMS, 2019-2025
26 companies · $1,775 in 2025
The $1,775 reported for 2025 was more than what 88% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $410 · 2020: $346 · 2021: $770 · 2022: $1,115 · 2023: $1,185 · 2024: $894 · 2025: $1,775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,708 · Education: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,708.02 |
| Education | $146.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $865.41 | 2019-2025 | Lokelma, Farxiga, Evusheld |
| Otsuka America Pharmaceutical, INC. | $711.32 | 2019-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $660.42 | 2020-2025 | Acthar, Terlivaz |
| Opko Pharmaceuticals, LLC | $574.53 | 2019-2025 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $499.32 | 2021-2025 | |
| Novo Nordisk INC | $450.37 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Calliditas Therapeutics US INC. | $441.75 | 2022-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $333.90 | 2022-2024 | |
| Fresenius USA Marketing, INC. | $316.62 | 2020-2025 | Velphoro, Velphoro |
| Amgen INC. | $291.92 | 2019-2025 | Repatha, Krystexxa, Tavneos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.16 | 2024-2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $199.55 | 2024-2025 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $190.03 | 2021-2025 | |
| Vifor Pharma, INC. | $130.46 | 2020-2024 | |
| Akebia Therapeutics INC | $116.82 | 2019-2025 | Vafseo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $90.73 | 2024-2025 | Yorvipath |
| Alexion Pharmaceuticals, INC. | $86.19 | 2022-2025 | Ultomiris |
| Mallinckrodt Enterprises LLC | $67.55 | 2019 | |
| Lilly USA, LLC | $56.94 | 2024-2025 | Jardiance |
| Ardelyx, INC. | $32.69 | 2025 | Ibsrela |
| Genzyme Corporation | $31.17 | 2019 | |
| Aurinia Pharma U.S., INC. | $25.44 | 2021-2022 | |
| Cormedix INC. | $24.19 | 2024 | Defencath |
| Ultragenyx Pharmaceutical INC. | $22.72 | 2021 | |
| Kyowa Kirin, INC. | $17.59 | 2025 | |
| Apellis Pharmaceuticals, INC. | $16.57 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raphael Higginbotham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.